Multiple myeloma (MM) is an incurable malignancy of plasma secreting B cells disseminated in the bone marrow. Successful utilization of oncolytic virotherapy for myeloma treatment requires a systemically administered virus that selectively destroys disseminated myeloma cells in an immune-competent host. Vesicular stomatitis virus (VSV)-expressing interferon-b (IFNb) is a promising new oncolytic agent that exploits tumor-associated defects in innate immune signaling pathways to destroy cancer cells specifically. We demonstrate here that a single, intravenous dose of VSV coding for IFNb (VSV-IFNb) specifically destroys subcutaneous and disseminated 5TGM1 myeloma in an immune-competent myeloma model. VSV-IFN treatment significantly prolonged survival in mice bearing orthotopic myeloma. Viral murine IFNb expression further delayed myeloma progression and significantly enhanced survival compared with VSV-expressing human IFNb. Evaluation of VSV-IFNb oncolytic activity in human myeloma cell lines and primary patient samples confirmed myeloma-specific oncolytic activity, but revealed variable susceptibility to VSV-IFNb oncolysis. The results indicate that VSV-IFNb is a potent, safe oncolytic agent that can be systemically administered to target and destroy disseminated myeloma effectively in immune-competent mice. IFNb expression improves cancer specificity and enhances VSV therapeutic efficacy against disseminated myeloma. These data show VSV-IFNb to be a promising vector for further development as a potential therapy for the treatment of MM.
INTRODUCTION
Multiple myeloma (MM) is a disseminated malignancy of terminally differentiated plasma cells residing primarily in the bone marrow. The disease is associated with bone destruction, anemia and compromised immune function. 1 Current treatments for MM, including stem cell transplantation and high-dose chemotherapy, have significantly prolonged median survival up to 6 years, but still fall short as a cure. There is a clear need for the development and testing of novel treatment options that can be delivered intravenously to reach and destroy disseminated disease sites. 2 Vesicular stomatitis virus (VSV) is a non-segmented, negative strand RNA virus of the Rhabdoviridae family that selectively kills malignant cells and has demonstrated oncolytic activity in various preclinical cancer models. 3 VSV infections normally occur in livestock, causing only mild symptoms during naturally occurring human infections. 4 Lethal infection of neural tissue in animal models prompted the use of viral engineering to attenuate VSV and minimize toxicity. 5, 6 Detection of viral infection in cells results in the activation of interferon (IFN) regulatory factors, and expression of Type I IFNs that can bind the a/b IFN receptor (IFNAR). a/b IFN receptor activation induces cellular innate immune responses by stimulating production of proteins that facilitate viral clearance by degrading viral intermediates, inhibiting translation, inducing apoptosis and activating release of pro-inflammatory cytokines. 7, 8 The Type I IFNs include several IFNa subtypes encoded by 14 IFNa genes and four IFNa pseudogenes, and IFNb, which is encoded by a single gene. 9 Although there have been differences described in receptor activation by IFNa and IFNb, 10 IFNb has been described to be expressed early upon viral detection, inducing IFN regulatory factor-7 expression that activates further expression of the various IFNa genes. 9 Of the five genes encoded by the VSV genome, the VSV matrix protein (M) facilitates evasion of innate immunity by blocking nucleocytoplasmic transport of mRNA preventing synthesis of IFN and other anti-viral or pro-inflammatory proteins. 11, 12 Aberrations leading to tumorigenesis also diminish innate immune response pathways, thereby rendering cancer cells susceptible to VSV replication and oncolysis. 8 VSV attenuation can be achieved by deleting (or mutating) residue 51 of the M protein (VSV-MD51) to reverse viral suppression of IFN synthesis 13 or by incorporation of the IFNb gene into the viral genome, 14 inducing IFNb expression and activation of downstream anti-viral genes including IFNa, to promote viral clearance from non-cancerous tissues. Cancer cells that are weakly responsive to IFN remain permissive to viral propagation and oncolysis.
The potential of VSV as a novel myeloma therapy was assessed in the immune-competent 5TGM1 model of MM. The 5TGM1 murine myeloma cell line can be implanted in C57Bl/KaLwRij syngeneic mice to form rapidly growing subcutaneous tumors or injected intravenously to induce orthotopic myeloma that can be monitored by measuring IgG2b paraprotein secreted by myeloma cells. 15 This allows novel MM therapies to be tested in a model that closely resembles disseminated myeloma in patients in the presence of intact anti-viral innate and adaptive immune responses.
Although VSV-MD51 has enhanced tumor specificity by inducing IFN production, viral replication is significantly compromised even in IFN-resistant cells. 16 Having previously demonstrated that recombinant VSV-MD51 coding for the sodium iodide symporter has weak anti-myeloma activity, 17 we hypothesized that VSV coding for IFN-b (VSV-IFNb) would specifically destroy cancer cells in vivo while maintaining viral potency. IFNa has historically been used as therapy against myeloma, albeit with weak and variable efficacy, and has been reported to have various antitumor properties, including direct pro-apoptotic activity, promotion of long-lasting antitumor immunity and inhibition of tumor blood vessel formation. 18 --20 IFNb, however, has been utilized extensively in various oncolytic viral vectors, including adenovirus, 21 vaccinia 22 and measles viruses, 23 demonstrating that viral vectors expressing IFNb can be safely and successfully utilized for the treatment of cancer. VSV-expressing IFNb has also previously shown antitumor efficacy in preclinical cancer models, including renal cell carcinoma 14 and malignant pleural mesothelioma, 24 whereas safety studies indicate that viral IFNb expression successfully alleviates VSV neurotoxicity, 5 making VSV-IFNb a potentially potent and safe vector for systemic treatment of MM.
Here we report the potent oncolytic activity of intravenously administered VSV-IFNb in an immune-competent model of MM. VSV is able to target specifically tumor sites in vivo inducing destruction of myeloma cells in subcutaneous tumors and within the bone marrow. Destruction of disseminated orthotopic myeloma resulted in transiently reduced and subsequently delayed disease burden and prolonged survival. Therapeutic efficacy was achieved in the presence of robust anti-viral antibody response with no detectable toxicity. We further demonstrate that VSV expressing murine IFNb (mIFNb) shows significantly enhanced therapy in mice bearing disseminated myeloma, making VSV-IFNb a strong candidate as a potential new therapeutic vector for the treatment of myeloma. Primary myeloma cells are grown in RPMI 1640 supplemented with 10% fetal bovine serum, and penicillin and streptomycin antibiotics and interleukin-6 (1 ng ml À1 ).
MATERIALS AND METHODS

Viruses
VSV coding for mIFNb and human IFNb (hIFNb) were generated in the lab of Dr Glen N. Barber (University of Miami School of Medicine, Miami, FL) as described previously. 14 The VSV-IFNb gene contains the IFNb gene at XhoI/ NheI restriction sites generated in between the G and L viral genes. VSV-GFP (VSV-expressing GFP) (Indiana strain) was also provided by Dr Glen N. Barber. VSV vectors were amplified using BHK-21 cells. BHK-21 cells plated in flasks were allowed to grow to B80% confluency. Cells were infected at a multiplicity of infection (MOI) of 0.01 for 1 h in serum-free Dulbecco's modified Eagle's medium. Virus was then removed and cells incubated at 37 1C in 5% CO 2 incubator. Complete cytopathic effect was seen by B48 h post infection. Culture medium was harvested, frozen in liquid nitrogen and thawed at 37 1C, subjected to low-speed centrifugation and filtered through a 0. In vitro viral activity Viral replication was compared by infection of BHK-21 cells plated in 24-well plates (1 Â 10 5 cells per well per ml). These cells were incubated overnight, and mock infected or infected with VSV-GFP, VSV-mIFNb and VSV-hIFNb (MOI of 3.0, in Opti-MEM at 37 1C for 1 h). Cell supernatant was harvested at specified time points and viral titer was measured using the previously described method and calculated using the Spearman and Karber equation.
Viral growth characteristics were measured in myeloma suspension cells mock infected or infected with VSV viruses in Opti-MEM. Cell supernatant was harvested at specified time points to measure viral titer (using the titer measurement protocol described above) and secreted IFNb by using an ELISA kit designed to detect mIFNb specifically (PBL InterferonSource 42400-1). Cells were harvested to measure viability by flow cytometry using the LIVE/DEAD fixable dead cell stain kit (Invitrogen Molecular Probes, Eugene, OR, USA). Assays to measure viable cell proliferation were carried out on myeloma cells and measured using the MTT (3-(4,5-dimethylthiazlyl-2)-2,-5-diphenyltetrozolium bromide) assay (ATCC 30--1010K). Cells were mock infected or infected with VSV-GFP, VSV-mIFNb or VSVhIFNb (MOI of 1.0 in Opti-MEM, 1 h at 37 1C). Virus was washed out and cells were seeded into 96-well plates (1 Â 10 4 cells per well per 100 ml) in their respective media. Plates were incubated for 72 h. MTT reagent (0.01 ml) was added to each well and incubated at 37 1C for 3 h. A measure of 0.1 ml detergent was added to cells to extract formazin and color intensity was measured using a microplate reader (570 nm). Experiments were performed in triplicate and results tabulated as a percentage of mock-infected cells.
In vivo studies
The 4-to 6-week-old female C57Bl/KaLwRij mice were obtained from Harlan (Horst, The Netherlands). Tumors were implanted in mice by a subcutaneous injection of 5 Â 10 6 cells in 100 ml PBS. Subcutaneous tumors were established by day 14 post 5TGM1 implantation. Tumor burden was monitored by serial caliper measurements to measure tumor volume. Mice were randomized and treated with a single, intravenous dose of 100 ml PBS (control treatment), VSV-mIFNb or VSV-hIFNb at a dose of 1 Â 10 8 TCID 50 per mouse. Mice reached sac criterion if tumor burden exceeded 10% of body weight, if mice were unable to access food or water or if tumors had indications of ulceration. Mice were culled at days 1 and 3 post VSV administration (n ¼ 2 per day). Tumor, brain and mouse serum was harvested. Serum was further harvested at days 5, 7, 10, 15 and 30 post VSV administration (two mice or surviving mice at each time point). Harvested tissues were processed and analyzed as described below. Orthotopic 5TGM1 myeloma was established in syngeneic C57Bl/KaLwRij mice by intravenous administration of 5 Â 10 6 5TGM1 cells. Mice were administered with a single, intravenous dose of 100 ml PBS, or VSV-mIFNb or VSV-hIFNb (5 Â 10 7 TCID 50 per mouse) at day 21 post-injection. Myeloma burden was monitored by measurement of serum IgG2b using mouse IgG2b ELISA Quantitation kit (Bethyl Laboratories, Montgomery, TX, USA; E90-109). Mice were monitored for symptoms of myeloma, including weight loss, hindlimb paralysis or the growth of subscapular plasmacytomas and killed according to the previously described criterion.
Tissue analysis
Serum collected at days 1 and 3 was analyzed for mIFNa and IFNb using IFNa and IFNb ELISA kits (PBL InterferonSource, Piscataway, NJ, USA). Serum was also used to measure generation of anti-VSV neutralizing antibodies. Serum was pre-incubated for 30 min at 56 1C to inactivate complement. Serial twofold dilutions of inactivated serum were incubated with 500 TCID 50 VSV-GFP for 1 h at 37 1C. The mixture of serum and virus was then plated onto Vero cells in 96-well plates. Anti-VSV antibody titer was quantified as the minimum dilution of serum that failed to protect Vero cells from VSV-induced complete cytopathic effect. Harvested organs, tumor and brain were segmented into two portions, one portion flash frozen and another portion stored in 10% formalin. Frozen tumor and brain sections were weighed, and macerated to form tissue suspension. Tissue suspension was subjected to two rounds of freeze --thaw (in liquid nitrogen) and centrifuged to collect tissue supernatant. Tissue supernatant was titered as previously described to measure viral recovery per mg of tissue. Tissues stored in formalin were embedded in paraffin, sectioned and subject to staining with hematoxylin and eosin. Tissue sections were subject to independent histopathological analysis by Dr Ronald Marler, Mayo Clinic (Scottsdale, AZ).
RESULTS
VSV-expressing IFNb has enhanced cancer specificity without viral attenuation Recombinant VSV coding for IFNb (VSV-IFNb) was generated by incorporation of the IFNb gene cDNA into the previously constructed pVSV-XN2 plasmid containing the full-length positive strand VSV antigenome.
14 PCR-generated IFNb cDNA was inserted into a unique restriction site between the viral G and L genes coding for the viral surface glycoprotein and polymerase protein, respectively. Functional virus was recovered as described previously. 25 Newly generated VSV-IFNb vectors, containing transgenes coding for either mIFNb (VSV-mIFNb) or hIFNb (VSV-hIFNb), had similar growth characteristics to VSV-GFP in BHK cells, a cell line that is not responsive to either mIFNb or hIFNb (not shown). VSV oncolytic efficacy against myeloma was initially assessed in vitro, indicating that VSV-GFP, VSV-mIFNb and VSV-hIFNb viruses replicate rapidly in 5TGM1 murine myeloma cells following infection at an MOI of 3.0 (Figure 1a) . VSV-mIFNb infection induced the expression of mIFNb (Figure 1b) , which did not impede VSV oncolysis of 5TGM1 cells compared with VSV-hIFNb and VSV-GFP (Figure 1c) . Evaluation of VSV-IFNb specificity indicated that VSV-mIFNb kills 5TGM1 myeloma cells, but has diminished cytotoxicity in SR-4987 immortalized bone marrow stromal cells. VSV-GFP, however, kills both cell types effectively in vitro (Figure 1d) . Overall these results demonstrate the ability of VSV-IFNb to target and kill 5TGM1 myeloma cells while exhibiting enhanced specificity in vitro with diminished potency in non-cancerous murine bone marrow stromal cells.
VSV-IFNb has potent therapeutic efficacy against MM in immunecompetent mice Safety studies with VSV-IFNb have previously demonstrated that viral expression of host-specific IFNb diminished toxicity in preclinical cancer models. 5 VSV-IFNb oncolytic efficacy against MM was assessed in vivo in C57Bl/KaLwRij bearing syngeneic 5TGM1 subcutaneous myeloma tumors. Mice were administered with a single, intravenous dose of 1 Â 10 8 TCID 50 VSV-mIFNb, VSVhIFNb or 100 ml PBS via tail vein injection. Tumor responses were monitored and categorized into tumor progression, tumor regression or regression, followed by relapse as shown (Figure 2a) . All mice treated with PBS had rapid tumor progression and were killed. In all, 100% of tumors regressed in response to VSV-mIFNb treatment, whereas 80% of tumors regressed following VSV-hIFNb treatment, with no associated symptoms of neurotoxicity. These tumor responses correlated with significantly prolonged survival of mice treated with VSV-mIFNb (**P ¼ 0.0018) or VSV-hIFNb (*P ¼ 0.04) compared with PBS-treated mice using logrank survival comparisons (data not shown). In vivo production of mIFNb or hIFNb was confirmed by the analysis of serum from treated mice at days 1 and 3 post VSV administration by ELISA (Figure 2b) . A small proportion of mice with regressing tumors relapsed and mice were eventually killed owing to tumor burden (Figure 2a) .
Adaptive immune responses against systemically administered virus in the form of neutralizing antibodies are a significant barrier to effective oncolytic virotherapy. 26, 27 VSV especially is a highly immunogenic virus. 28 Neutralizing antibodies were detected in the serum by day 5 post-treatment, with no significant difference in antibody titer generated between VSV-mIFNb-and VSV-hIFNb-treated mice (Figure 2c) . No anti-VSV neutralizing antibodies were detected in PBS-treated mice. Overall these data indicate that systemically administered VSV-IFNb has potent and specific activity against myeloma tumors in vivo in immune-competent mice. At this dose level, VSV-IFNb demonstrates oncolytic efficacy with no associated toxicity, regardless of mIFNb expression. The transient expression of detectable IFNb and rapid generation of neutralizing antibodies against VSV-IFNb suggests that tumor regression occurs in response to a limited period of viral activity before antibody-mediated viral clearance, prompting further analysis of early tumor-specific viral activity.
VSV-mIFNb specifically and rapidly destroys myeloma tumors VSV-IFNb activity in vivo was further evaluated by the analysis of tumors and brains harvested from mice following intravenous virus treatment. Brain tissues were analyzed to monitor potential VSV toxicity, which proceeds by infection of neural tissues. 6, 29 Portions of tumors and brains from PBS-and VSV-mIFNb-treated mice were sectioned and stained using hematoxylin and eosin. Histopathological analysis of harvested tumors showed extensive necrosis in tumors from VSV-mIFNb-treated mice, with low to no necrosis in PBS-treated mice (Figures 3a and b) . The degree of tumor necrosis was quantified, indicating increased tumor cell death at day 3 post VSV-mIFNb treatment (Figure 3c ). To confirm that tumor destruction was associated with viral oncolysis, supernatants from processed tumors were titered showing viral load of approximately 1 Â 10 5 TCID 50 per mg of tissue in VSVmIFNb-treated mice and 1 Â 10 3 TCID 50 per mg of tissue in VSVhIFNb-treated mice (Figure 2c ). Although the differences are not significant, tumor-specific viral burden and degree of tissue necrosis increased from day 1 to day 3 post viral administration, suggesting that VSV is able to undergo effectively both viral replication and by 72 h induce cell death in 450% of tumor cells. There were no indications of necrosis or inflammation, or virus recovered from brains of VSV-IFNb-treated mice (Figure 3a and data not shown).
Of note, histopathological analysis revealed minimal to negligible infiltration of immune cells at the site of tumor at days 1 and 3 post-treatment, suggesting that neither the presence of virus nor viral destruction of tumor cells stimulated early infiltration of inflammatory immune cells. Analysis of tumors at day 15 post PBS, VSV-mIFNb or VSV-hIFNb administration indicated slight mixed inflammatory infiltrate, including macrophages and lymphocytes in tumors treated with VSV-mIFNb (Table 1 ). This suggests that mIFNb expression may enhance late infiltration of immune cells at tumor site. These data collectively indicate that systemically administered VSV-IFNb localizes to the site of tumor to induce tumor destruction. There is no observed toxicity and no detectable virus in the brain demonstrating that VSV-IFNb can be safely administered intravenously at this dose level.
VSV-IFNb has potent therapeutic efficacy against disseminated myeloma The potent efficacy of systemically administered VSV-IFNb against subcutaneous myeloma tumors prompted studies to evaluate the ability of VSV-IFNb to reach and destroy disseminated myeloma. Orthotopic myeloma was established in mice by intravenous implantation of 5TGM1 cells. 5TGM1 myeloma cells, like myeloma in patients, secrete monoclonal antibodies, specifically an IgG2b serum paraprotein. Myeloma burden was assessed by IgG2b ELISA as described previously. 17 ELISA quantification of serum IgG2b showed a significant increase by day 21 post 5TGM1 injection indicative of increasing myeloma burden (Figure 4a ; **P ¼ 0.0019). Myeloma burden and survival were monitored following PBS, VSVmIFNb or VSV-hIFNb treatment. PBS-treated mice had rapidly progressing myeloma and were killed owing to weight loss or hindlimb paralysis. A single, intravenous dose of 5 Â 10 7 TCID 50 and subsequently used to infect Vero cells. Measured antibody titer is the minimum serum dilution that fails to protect against VSVinduced complete cytopathic effect (CPE). Serum was harvested from n ¼ 2 mice per groups at each time point, except where only one mouse was surviving in the treatment group.
VSV-mIFNb or VSV-hIFNb delayed myeloma progression and significantly prolonged survival of myeloma bearing mice (Figures  4b and c) . Analysis of spine and femur sections harvested from myeloma bearing mice at 48 h post-treatment showed foci of myeloma cells packed in the bone marrows of PBS-treated mice, whereas bone marrows of VSV-IFNb-treated mice contained regions of necrosis, indicating that VSV-IFNb could reach and destroy disseminated foci of myeloma within the bone marrow ( Figure 5 ). There was no appreciable inflammatory infiltrate within the bone marrow of either PBS-, VSV-mIFNb-or VSV-hIFNb-treated mice at 48 h post-treatment. We further observed that systemic VSV-mIFNb treatment significantly prolonged survival of mice bearing disseminated myeloma compared with VSV-hIFNb-treated mice, with one mouse being completely cured of systemic disease (*P ¼ 0.021). The basis of IFNb-induced enhancement of oncolytic efficacy in mice with disseminated myeloma is as yet unknown, although the hypotheses include direct anti-myeloma activity, IFNb effects on the bone marrow microenvironment and potentially IFNb-induced antitumor immune responses.
VSV coding for IFNb has variable oncolytic activity in myeloma cells Systemically administered VSV-IFNb has demonstrated potent in vivo efficacy against both subcutaneous and disseminated myeloma, indicating that VSV-IFNb is a promising oncolytic candidate for myeloma therapy. These studies, however, have been limited to the evaluation of viral oncolytic activity in 5TGM1 cells and in mice bearing 5TGM1 myeloma. The use of VSV-IFNb as a potential anti-myeloma therapy will depend on the ability of VSV-IFNb to exert oncolytic activity on various types of myeloma. A panel of human myeloma cell lines was infected with VSVmIFNb or VSV-hIFNb and cell viability was measured 72 h later. These data show firstly that VSV-mIFNb is potently cytopathic against all myeloma cell lines in the selected panel including HS27A, a human bone marrow stromal cell line (Figure 6a ). HS27A cells, however, were relatively resistant to VSV-hIFNb oncolysis, indicating that viral expression of hIFNb suppresses VSV-induced cell death in responsive human bone marrow stromal cells. hIFNb production also diminished VSV oncolytic activity in four of the six cell lines in the myeloma panel, indicating that these cells were responsive to IFNb production, albeit weakly when compared with non-cancerous bone marrow stromal cells (Figure 6a ). These data indicate that oncolytic activity of VSV-IFNb may be diminished in myeloma cells that retain responsiveness to IFN. VSV-IFNb antimyeloma activity was also assessed in primary myeloma cell lines. Viral oncolytic activity and specificity are gauged by measuring the ability of VSV-hIFNb to kill five primary patients samples sorted into CD138 þ myeloma cells and CD138 À non-myeloma cells. Cell death following infection was measured by staining cells with a dead cell marker and monitored using flow cytometry. In four out of five samples, 480% of CD138 þ myeloma cells were killed. In comparison, CD138
À cells were resistant to VSV-hIFNb oncolysis (Figure 6b ). These results demonstrate the specific activity of VSVhIFNb against myeloma cell lines and primary myeloma cells. Viral hIFNb expression enhances specificity of VSV oncolytic activity demonstrated by the diminished ability of VSV-hIFNb to kill human bone marrow stromal cells. hIFNb expression in human myeloma cells may, however, potentially attenuate VSVIFNb oncolytic activity depending on how significantly innate immune pathways are impaired in cancer cells and resultant responsiveness to IFN induction. Overall the results support the hypothesis that IFNb expression enhances the specificity of VSV, exerting cytopathic activity against various types of human myeloma cell lines and in primary myeloma cells, with diminished activity in non-cancerous bone marrow stromal cells and CD138
À cells.
DISCUSSION
Viral attenuation is utilized to decrease potential toxicity of oncolytic viral cancer therapies. 8, 30 Clinical studies testing oncolytic viruses have demonstrated limited therapeutic efficacy of systemically administered viral treatments, indicating that viral engineering utilized to enhance tumor specificity also debilitate viral replication and oncolysis. 31 The use of VSV-IFNb as a potential anticancer agent allows utilization of a viral vector with intact and functional viral genes that produces exogenous IFNb. The results demonstrate that VSV-IFNb retains robust viral replication and oncolytic potency in 5TGM1 myeloma cells while exhibiting diminished ability to kill non-cancerous cells.
There are various in vivo barriers to effective systemic oncolytic virotherapy. These include off-target sequestration, complement inactivation, cellular innate immunity, neutralizing antibodies and physical barriers such as tumor stroma that prevent effective viral propagation and spread. 7,32 --34 In our studies, therapeutic efficacy is achieved following a single, intravenous dose of VSV-IFNb in an immune-competent myeloma mouse model. These data indicate that sufficient virions of systemically administered VSV-IFNb reach the tumor site, and selectively propagate within and kill myeloma cells to exert potent and specific antitumor activity. The absence of neurotoxicity indicates insubstantial off-target replication at this dose of VSV-IFNb, although previous studies have demonstrated that IFNb expression alleviates viral toxicity at high doses. 5 The potent tumor-specific activity of intravenous VSV-IFNb against myeloma tumors warrants further investigation into the processes and roles of viral extravasation, propagation and virus-induced cell death in mediating successful tumor destruction.
Our results demonstrate that VSV-expressing mIFNb induction delays myeloma progression and improves survival compared with VSV-expressing hIFNb that is not functional in mouse tissues. This indicates that while IFNb can alleviate potential VSV neurotoxicity, it also enhances VSV antitumor efficacy in myeloma bearing immune-competent mice. It will be important to further understand the basis of IFNb-induced enhancement of therapeutic efficacy in mice with disseminated myeloma. IFN has been used as a therapy for the treatment of myeloma and tested against other malignancies with limited success 18 and viral IFNb expression may exert direct antitumor effects on myeloma cells or the bone marrow microenvironment. Tumor histology indicates that mIFNb expression does not affect early, but may promote late infiltration of immune cells within 5TGM1 myeloma tumors, suggesting that IFNb could enhance the antitumor immune response. 35 Further investigations are underway to delineate specific mechanisms by which IFNb induction enhances VSV oncolytic efficacy against disseminated myeloma.
Currently used myeloma therapies have extended the life expectancy of patients diagnosed with myeloma, but are not curative. Refractory or relapsed myeloma evolve mechanisms to resist chemotherapies. 36 The studies described here demonstrate the ability of VSV-IFNb to target and destroy disseminated myeloma to delay myeloma progression and improve survival in mice. VSV-IFNb destroys myeloma cells based on systematic weaknesses in cellular innate immunity that arise from various tumorigenic alterations. 37 In addition, VSV-IFNb infection results in (variably) reduced viability of human myeloma cell lines and primary patient samples. The potential ability of VSV-IFNb to kill different types of myeloma cells and the rapidity of VSV-IFNb oncolysis (450% tumor destruction by 72 h post-treatment) reduces the likelihood that myeloma cells can escape or evolve to resist viral oncolysis, both features that favor the proposed utilization of VSV-IFNb as a potential myeloma therapy.
Viral IFNb induction can potentially either enhance VSV therapeutic efficacy against disseminated myeloma or attenuate viral propagation in target cells that respond to IFNb. It will be important in future studies to test VSV-IFNb efficacy in different immune-competent models of MM, firstly to validate that viral efficacy is not limited to this specific model of MM and additionally to shed further light into the role of viral IFNb expression in successful tumor oncolysis. The data demonstrate overall that VSV-IFNb is a potent oncolytic candidate for clinical use for myeloma treatment and a promising platform for further engineering to improve viral targeting, monitoring and therapy. 
